Add Formweb to your mobile device
System Formulary Update
Antipsychotics, First Generation Formulary Update
Situation
The antipsychotics, first generation class review and formulary standardization was approved at the September 2021 System Pharmacy and Therapeutics Committee meeting.
Background
The following medications were reviewed: chlorpromazine, droperidol, fluphenazine, haloperidol, loxapine, molindone, perphenazine, pimozide, prochlorperazine, thioridazine, thiothixene, trifluoperazine
Assessment/Recommendation
Changes effective: Tuesday, November 16, 2021
System P&T voted to include the following products on the UNC Health Medication Formulary:
- Chlorpromazine injection and tablet
- Droperidol injection
- Fluphenazine injection (deaconate and HCl) and tablet
- Haloperidol injection (deaconate and lactate), oral solution, and tablet
- Loxapine capsule
- Perphenazine tablet
- Prochlorperazine injection and tablet
- Thiothixene capsule
- Trifluoperazine tablet
Note: Stock of these formulary products may vary at individual entities
As a result, the following products will be removed from the UNC Health Medication Formulary:
- Fluphenazine oral elixir and oral concentrate solution
- Loxapine aerosol inhalation
- Molindone
- Pimozide
- Prochlorperazine rectal suppository
- Thioridazine
Non-formulary orders will be converted according to the following therapeutic interchange:
Antipsychotics, First Generation |
|
|
Non-Formulary Order |
Formulary Equivalent Order |
|
Amitriptyline-perphenazine combination product |
Equivalent dose of amitriptyline + perphenazine |